Reference : Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/10772
Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
English
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Paquot, Nicolas mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
2009
Best Practice & Research. Clinical Endocrinology & Metabolism
Bailliere Tindall
23
1
103-16
Yes (verified by ORBi)
International
1521-690X
1532-1908
London
Netherlands
[en] Abdominal obesity is associated with numerous metabolic abnormalities, including insulin resistance, impaired glucose tolerance/type-2 diabetes, and atherogenic dyslipidaemia with low high-density lipoprotein (HDL) cholesterol, high triglycerides, and increased small dense low-density lipoprotein (LDL) cholesterol. A proportion of these metabolic disorders may be attributed to increased endocannabinoid activity. The selective cannabinoid 1 (CB1) receptor antagonist rimonabant has been shown to reduce body weight, waist circumference, insulin resistance, triglycerides, dense LDL, C-reactive protein (CRP), and blood pressure, and to increase HDL and adiponectin concentrations in both non-diabetic and diabetic overweight/obese patients. Besides an improvement in glucose tolerance in non-diabetic subjects, a reduction of 0.5-0.7% in haemoglobin A1C (HbA(1c)) levels was consistently observed in various groups of patients with type-2 diabetes. Almost half the metabolic changes could not be explained by weight loss, supporting direct peripheral effects of rimonabant. Ongoing studies should demonstrate whether improved metabolic disorders with CB1 receptor antagonists (rimonabant, taranabant, etc.) would translate into fewer cardiovascular complications among high-risk individuals.
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/10772
10.1016/j.beem.2008.09.001
http://www.sciencedirect.com/science/journal/1521690X

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Use of cannabinoid CB1 receptor antagonists for the.pdfPublisher postprint275.21 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.